From Science to Patients – Ideas Become Treatments at CureVac

CureVac already has several active ingredients in research and (pre-)clinical development for the treatment of cancer and for protection against infectious diseases. Until today, CureVac has tested its mRNA-based products in several clinical studies.

Our success is tangible, inspiring us to continue on our path every day.

CureVac's Pipeline

RNA-based Cancer Therapies
Research
Pre-clinic
Phase I
Phase II
Phase III
Sponsor
NSCLC (RNActive®, Combination BI 1361849 / CV9202 with CPI)
Phase I
Boehringer Ingelheim & Ludwig Cancer Research
NSCLC (RNActive®, Combination BI 1361849 / CV9202 with CPI)
Pre-clinic
Boehringer Ingelheim
Superficial tumors (TLR-/RIG-I agonist CV8102, i.t., combination + CPI)
Phase I
CureVac

CureVac’s TLR-/RIG-I agonist (CV8102) is a potent immunomodulator designed to expand the effects of immuno-oncology treatments and prophylactic vaccines for the prevention of infectious diseases.

Current Status: Phase I

Targeted tumors are melanoma, squamous cell carcinoma of skin, head and neck, adenoid cystic carcinoma.

For further information on this study please visit clinicaltrials.gov.

Hepatocellular carcinoma (RNAdjuvant® / multipeptide vaccine)
Phase I
Hepavac
Superficial tumors (RNArt® / RNAntibody®)
Pre-clinic
CureVac
Different indications (RNActive® Neoantigens in comb. with CPI)
Pre-clinic
Lilly
Further undisclosed mRNA cancer therapies
Research
CureVac
RNA-based Prophylactic Vaccines (RNActive®)
Research
Pre-clinic
Phase I
Phase II
Phase III
Sponsor
Rabies (CV7202, next generation formulation)
Phase I
CureVac
Influenza (CV7301, next generation formulation)
Pre-clinic
CureVac
Diverse projects (i.e. Malaria, Influenza)
Research
Bill and Melinda Gates Foundation
RSV
Research
CureVac
HIV
Research
IAVI
Outbreak/ Emerging targets
Pre-clinic
CureVac
RNA-based Molecular Therapies
Research
Pre-clinic
Phase I
Phase II
Phase III
Sponsor
Rare Disease Enzyme Replacement (undisclosed target)
Research
CureVac
Gene-editing (liver)
Pre-clinic
CRISPR
RNAntibody®
Pre-clinic
undisclosed
Further undisclosed projects
Pre-clinic
CureVac